Disease · MONDO_0005468
Comparisons in its trials22
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 22
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Restrictive Fluids vs Liberal Fluids: serious adverse events | 18 of 782 | 19 of 781 | 1,563 | NCT03434028 | Trial comparisons |
| Restrictive Fluids vs Liberal Fluids: New Onset Atrial or Ventricular Arrhythmia | 59 of 779 | 67 of 778 | 1,557 | NCT03434028 | Trial comparisons |
| Restrictive Fluids vs Liberal Fluids: Death From Any Cause at Any Location by Day 90 | 172 of 768 | 169 of 773 | 1,541 | NCT03434028 | Trial comparisons |
| Restrictive Fluids vs Liberal Fluids: deaths from any cause | 172 of 768 | 169 of 773 | 1,541 | NCT03434028 | Trial comparisons |
| Restrictive Fluids vs Liberal Fluids: Development of ARDS | 19 of 757 | 20 of 758 | 1,515 | NCT03434028 | Trial comparisons |
| Restrictive Fluids vs Liberal Fluids: Initiation of Renal Replacement Therapy | 24 of 738 | 24 of 738 | 1,476 | NCT03434028 | Trial comparisons |
| Restrictive Fluids vs Liberal Fluids: New Intubation With Invasive Mechanical Ventilation by 28 Days | 77 of 701 | 87 of 687 | 1,388 | NCT03434028 | Trial comparisons |
| Midodrine vs Placebo: Rates of ICU Readmission | 1 of 66 | 3 of 66 | 132 | NCT01531959 | Trial comparisons |
| Midodrine vs Placebo: deaths from any cause | 0 of 66 | 1 of 66 | 132 | NCT01531959 | Trial comparisons |
| Midodrine vs Placebo: Rates of Hypertension, Bradycardia, and Hemodynamically Significant Tacharrythmias | 12 of 66 | 3 of 66 | 132 | NCT01531959 | Trial comparisons |
| Midodrine vs Placebo: serious adverse events | 0 of 66 | 1 of 66 | 132 | NCT01531959 | Trial comparisons |
| Ondansetron vs Placebo: serious adverse events | 0 of 25 | 0 of 27 | 52 | NCT01841606 | Trial comparisons |
| Midodrine vs Placebo: deaths from any cause | 0 of 19 | 0 of 19 | 38 | NCT02307565 | Trial comparisons |
| Midodrine vs Placebo: serious adverse events | 0 of 19 | 0 of 19 | 38 | NCT02307565 | Trial comparisons |
| Dopamine Treatment vs Vasopressin Treatment: Number of Subjects in Each Group Who Have Achieved an Optimal Mean Blood Pressure Value at 24 Hours of Life | 9 of 10 | 9 of 10 | 20 | NCT01318278 | Trial comparisons |
| Angiotensin vs Control: Mortality | 5 of 10 | 6 of 10 | 20 | NCT01393782 | Trial comparisons |
| Angiotensin vs Control: deaths from any cause | 5 of 10 | 6 of 10 | 20 | NCT01393782 | Trial comparisons |
| Angiotensin vs Control: serious adverse events | 0 of 10 | 0 of 10 | 20 | NCT01393782 | Trial comparisons |
| Day 1 - No Drug vs Day 2 - Pyridostigmine Bromide: serious adverse events | 0 of 10 | 2 of 10 | 20 | NCT02307526 | Trial comparisons |
| B12a vs Placebo: Death | 0 of 4 | 0 of 4 | 8 | NCT03735316 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005468/comparisons